Drug Master Files, manufacturer listings, and Electronic Common Technical Document (eCTD) submissions are foundational to regulatory compliance. Yet even experienced regulatory, quality, and operations...
The global Unique Device Identification (UDI) landscape is entering a critical enforcement phase — and 2026 will be a challenging year for medical device manufacturers operating in the European Union...
The FDA’s final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for FDA-assigned National Drug Codes (NDCs) ...
UDI product data is now due for specific scenarios (enforced as of December 8, 2022). Class I and Unclassified medical devices that are required to be labeled with a UDI code must submit product data...
LexisNexis Life Sciences Solutions and ONIX expand strategic alliance to guide pharma customers to market faster Professionals in the life sciences industry rely on unique regulatory affairs expertise...
The global Unique Device Identification (UDI) landscape is entering a critical enforcement phase — and 2026 will be a challenging year for medical device manufacturers operating in the European Union, Australia, and Switzerland.
Health authorities are migrating from system development/launch to system enhancement/maintenance and placing more attention on active oversight and industry mandatory compliance. For companies marketing medical devices internationally, the new 2026 UDI regulations and compliance enforcement require stronger data governance, coordinated submission strategies, and ongoing lifecycle management.
Here's what you need to know.
Several key regulatory developments are converging:
For global manufacturers, these changes introduce parallel compliance obligations across multiple regulatory databases.
Under enacted UDI regulations, health authorities require and are expected to enforce UDI compliance:
Every packaging update, design modification, or regulatory status change may require corresponding updates in EUDAMED, AusUDID, or swissdamed.
Manufacturers without centralized UDI data governance risk inconsistencies, submission errors, and inspection findings.
Although global UDI systems align around recognized IMDRF policies and issuing agencies (GS1, HIBCC, ICCBBA), each jurisdiction maintains distinct:
This means global UDI compliance requires both harmonized data strategy and localized execution.
With multiple new UDI regulations and added scrutiny taking effect in 2026, UDI compliance and data quality is becoming a core regulatory priority. Incomplete or inaccurate records can delay market access and elevate regulatory risk.
Leading manufacturers are responding by:
Organizations that proactively prepare for 2026 UDI enforcement will be better positioned to reduce operational risk and support long-term global market access.
Managing EUDAMED, AusUDID, and swissdamed requirements simultaneously can strain internal resources. LexisNexis Life Sciences Solutions helps manufacturers simplify global UDI compliance across the entire product lifecycle — from initial data preparation and submission to ongoing updates, change management, and post-market compliance.
Our regulatory expertise and technology-driven solutions help ensure your device data remains accurate, synchronized, and inspection-ready across global markets.
As 2026 progresses, preparation is no longer optional. Now is the time to strengthen your global UDI strategy and implement a global UDI solution. Get in touch with us today to discuss your needs.
Contact us